CryoLife (CRY) Reports Q2 EPS of $0.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Piper Jaffray Remains Bullish on CryoLife (CRY) Following 2Q Report
July 26, 2016 7:54 AM EDTPiper Jaffray reiterated an Overweight rating and $16.00 price target on CryoLife (NYSE: CRY) following the company's 2Q earnings report. CRY reported revenue of $47.1M, driven by recently acquired On-X, improvements to the vascular tissue business, and strong BioGlue sales. Adjusted cash EPS of $0.13 beat the consensus of $0.07.... More
